Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Tranquility Partners LLC

Tranquility Partners LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 107.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,656 shares of the life sciences company’s stock after acquiring an additional 1,895 shares during the quarter. Tranquility Partners LLC’s holdings in Illumina were worth $489,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Illumina in the 4th quarter valued at $448,000. Van ECK Associates Corp lifted its position in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after acquiring an additional 22,718 shares in the last quarter. Leavell Investment Management Inc. acquired a new stake in Illumina in the fourth quarter valued at approximately $207,000. Kestra Private Wealth Services LLC raised its stake in shares of Illumina by 8.6% during the fourth quarter. Kestra Private Wealth Services LLC now owns 5,679 shares of the life sciences company’s stock valued at $759,000 after purchasing an additional 449 shares during the period. Finally, Stephens Inc. AR boosted its stake in shares of Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 2.9 %

Shares of NASDAQ:ILMN opened at $103.57 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a 50 day moving average price of $135.10 and a 200 day moving average price of $135.34. Illumina, Inc. has a 1-year low of $99.35 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. As a group, equities analysts forecast that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut their price objective on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, February 7th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.